Cystatin C Catches Kidney and Heart Risk That Standard Blood Tests Miss
Cystatin C is a small protein (13 kDa) produced by all nucleated cells in the body and cleared almost entirely through glomerular filtration in the kidneys. Because your serum level closely mirrors how well your kidneys are filtering, it serves as a powerful window into both kidney health and the cardiovascular trouble that often travels with it.
Why Creatinine Alone Can Be Misleading
Creatinine, the standard marker used to estimate kidney function, has a well-known blind spot: it is heavily influenced by muscle mass, age, and sex. A small, older adult and a young bodybuilder can have very different creatinine levels with identical kidney function.
Cystatin C sidesteps much of that problem. Research consistently shows it is less affected by age, sex, and muscle mass than creatinine. That said, cystatin C is not perfectly neutral either. Factors like inflammation, BMI, smoking, and certain medications (notably steroids and immunosuppressants) can influence levels. But on balance, it provides a clearer signal of actual filtration capacity.
| Marker | Main Strength | Main Limitation |
|---|---|---|
| Creatinine | Cheap, widely available, well-established | Skewed by muscle mass, age, sex |
| Cystatin C | Less affected by body composition; better at detecting early decline | Influenced by inflammation, BMI, smoking, some drugs |
| Combined (creatinine + cystatin C) | Most accurate eGFR estimate and best risk stratification | Requires both tests |
The "Preclinical" Kidney Problem You Won't See on a Standard Panel
One of the most striking findings in the research involves community-dwelling elderly adults whose creatinine-based eGFR is 60 or above, a level generally considered normal or only mildly reduced. In this group, elevated cystatin C identifies a state researchers describe as "preclinical" kidney dysfunction. These individuals face higher risks of death, heart failure, heart attack, stroke, and future chronic kidney disease, none of which their creatinine results would have flagged.
This matters because it means a clean creatinine result can provide false reassurance, particularly in older adults whose muscle mass naturally declines with age.
A Cardiovascular Marker, Not Just a Kidney Marker
Cystatin C's value extends well beyond estimating how your kidneys are filtering. Across studies in people with coronary artery disease and after acute coronary syndrome, higher cystatin C independently predicts major cardiovascular events, heart failure, and cardiovascular death. It outperforms both creatinine alone and creatinine-based eGFR for these predictions.
This makes cystatin C something unusual: a single biomarker that simultaneously tracks kidney filtration and cardiovascular prognosis. Elevated levels signal trouble on both fronts, even when traditional measures look reassuring.
Who Benefits Most From Cystatin C Testing
The research identifies several groups where cystatin C adds the most value over standard creatinine testing:
- Older adults. Age-related loss of muscle mass can mask kidney decline when relying on creatinine alone.
- People with coronary artery disease or after acute coronary syndrome. Cystatin C predicts cardiovascular events and mortality more accurately than creatinine-based measures.
- Certain ethnic groups. In South Asian UK Biobank participants, cystatin C reclassified many people with "normal" creatinine results into lower eGFR categories carrying substantially higher cardiovascular and mortality risk.
- Neonates. Cystatin C appears more sensitive for detecting acute kidney injury in newborns.
- Drug dosing decisions. For medications cleared by the kidneys, cystatin C often better predicts actual drug levels in the body than creatinine-based estimates.
The available research doesn't specify exactly when in a clinical workup cystatin C should be ordered versus creatinine, but the direction is clear: guidelines increasingly recommend it for more accurate assessment of kidney function and cardiorenal risk.
Combining Both Tests Gives the Sharpest Picture
If cystatin C is better than creatinine in many settings, should it simply replace creatinine? The evidence points toward a "both, not either" approach. The CKD-EPI equation that combines creatinine and cystatin C yields the most accurate eGFR estimate and the best risk stratification for outcomes like cardiovascular disease, end-stage kidney disease, and death.
Meta-analyses and large cohort studies reinforce that this combined approach detects more CKD cases and correlates more strongly with adverse outcomes than creatinine-based eGFR alone.
What This Means If You're Tracking Your Own Health
Cystatin C is not yet a routine part of most standard lab panels, but it is widely available and increasingly recognized. If any of the following apply to you, it is worth discussing with your doctor:
- You are over 60 and your creatinine-based eGFR looks "normal" but you have cardiovascular risk factors.
- You have known coronary artery disease or have had an acute coronary event.
- Your body composition (low muscle mass, very high or low BMI) might make creatinine unreliable.
- You take medications cleared by the kidneys and want more precise dosing guidance.
A single cystatin C measurement, or better yet the combined creatinine-cystatin C eGFR, could reveal risk that standard labs quietly miss. In a medical system that still leans heavily on creatinine, knowing this test exists puts you one step ahead.
